BackClarus Therapeutics Holdings Overview

Clarus Therapeutics Holdings Minority Interest

Clarus Therapeutics Holdings's minority interest is $0.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer trimmed avg / median

Loading

Clarus Therapeutics Holdings Minority Interest History

Loading

Clarus Therapeutics Holdings vs. peers: Minority Interest Comparison

Loading

Clarus Therapeutics Holdings Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Clarus Therapeutics Holdings (CRXT) FAQ

The latest minority interest for CRXT is $0 as of June 2022. In the prior-year period, the figure was $0. Investors often review this figure alongside Clarus Therapeutics Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRXT's minority interest moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Clarus Therapeutics Holdings's operating scale or balance-sheet position.

A minority interest figure of $0 for CRXT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CRXT's minority interest ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.